Filing Details

Accession Number:
0001764013-23-000087
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-08-08 16:44:48
Reporting Period:
2023-08-07
Accepted Time:
2023-08-08 16:44:48
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1764013 Immunovant Inc. IMVT Biological Products, (No Disgnostic Substances) (2836) 832771572
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1796309 Peter Salzmann C/O Immunovant, Inc.
320 W 37Th Street, 6Th Floor
New York NY 10018
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-08-07 101,339 $21.73 1,129,797 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. On August 3, 2021, the holder was granted 570,613 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 4, 2021, of which the remaining 356,633 of these RSUs vested on August 3, 2023. Settlement was deferred with respect to 178,317 of the vested RSUs. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of 178,316 of the RSUs and do not represent a discretionary sale by the holder.
  2. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.26 - $22.22 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.